These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Review of comparative effectiveness of treatments to prevent fractures. Black DM; Boonen S; Delmas P; Lyles KW Ann Intern Med; 2008 Jun; 148(11):885-6; author reply 887. PubMed ID: 18519940 [No Abstract] [Full Text] [Related]
5. Review of comparative effectiveness of treatments to prevent fractures. Karis R Ann Intern Med; 2008 Jun; 148(11):886; author reply 887. PubMed ID: 18519942 [No Abstract] [Full Text] [Related]
6. [New bone density conservation agents for osteoporosis under research and development: ED-71]. Hagino H Nihon Rinsho; 2007 Nov; 65 Suppl 9():454-8. PubMed ID: 18161148 [No Abstract] [Full Text] [Related]
7. Review of comparative effectiveness of treatments to prevent fractures. Rosen H Ann Intern Med; 2008 Jun; 148(11):884; author reply 887. PubMed ID: 18519939 [No Abstract] [Full Text] [Related]
8. My doctor wanted me to start taking Evista (raloxifene hydrochloride) for osteoporosis, but I'm worried because the drug is linked to a risk of blood clots. I have mild hypertension that I manage with medications, diet and exercise. Do you think the drug is safe? Heart Advis; 2010 May; 13(5):8. PubMed ID: 22816154 [No Abstract] [Full Text] [Related]
9. Osteoporosis - new treatments and updates. Honig S Bull NYU Hosp Jt Dis; 2011; 69(3):253-6. PubMed ID: 22035439 [No Abstract] [Full Text] [Related]
10. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. MacLean C; Newberry S; Maglione M; McMahon M; Ranganath V; Suttorp M; Mojica W; Timmer M; Alexander A; McNamara M; Desai SB; Zhou A; Chen S; Carter J; Tringale C; Valentine D; Johnsen B; Grossman J Ann Intern Med; 2008 Feb; 148(3):197-213. PubMed ID: 18087050 [TBL] [Abstract][Full Text] [Related]
11. Re: Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance. Hamaya E; Sowa H Menopause; 2014 Jan; 21(1):109-10. PubMed ID: 24281238 [No Abstract] [Full Text] [Related]
12. Fracture risk and treatment in chronic kidney disease. Connelly K; Collister D; Tangri N Curr Opin Nephrol Hypertens; 2018 May; 27(3):221-225. PubMed ID: 29547405 [TBL] [Abstract][Full Text] [Related]
13. In reply. Urushihara H Menopause; 2014 Jan; 21(1):110. PubMed ID: 24326283 [No Abstract] [Full Text] [Related]
15. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Cranney A; Adachi JD Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357 [TBL] [Abstract][Full Text] [Related]
16. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate]. Shiraki M Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147 [No Abstract] [Full Text] [Related]
17. Questioning the accuracy of a recent review of osteoporosis medications. Kuhl LN; Ettinger B; Rosen CJ; Col NF Ann Intern Med; 2009 Mar; 150(6):423-4; author reply 424-5. PubMed ID: 19293078 [No Abstract] [Full Text] [Related]
19. Hypocalcemia induced by raloxifene. Vu TD; Varadarajan S; Seeman E; Jerums G; MacIsaac RJ Curr Drug Saf; 2012 Apr; 7(2):176-8. PubMed ID: 22873502 [TBL] [Abstract][Full Text] [Related]
20. Drug treatment for low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med; 2008 Sep; 149(6):I46. PubMed ID: 18794555 [No Abstract] [Full Text] [Related] [Next] [New Search]